NCT03920007 - Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 12, 2019

Primary Completion Date

May 19, 2023

Study Completion Date

May 19, 2027

Conditions

Leber Congenital AmaurosisLCALCA1

Interventions

DRUG

ATSN-101

Pharmaceutical form:Solution for intraocular administration Route of administration: Subretinal injection

DRUG

ATSN-101 Diluent Solution

Pharmaceutical form:Solution for parenteral use Route of administration: Subretinal injection

DRUG

Prednisone

Pharmaceutical form:Tablet Route of administration: Oral

DRUG

Triamcinalone Acetonide

Pharmaceutical form:Suspension Route of administration: Peri-ocular injection

DRUG

1% Prednisolone

Pharmaceutical form:Suspension Route of administration: Drops

DRUG

Trimethoprim/polymyxin B

Pharmaceutical form:Solution Route of administration: Topical

Trial Locations (2)

Scheie Eye Institute, University of Pennsylvania, Philadelphia

Casey Eye Institute - Oregon Health & Science University, Portland